Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis

Authors: Guanghua Li, Zhao Wang, Jianbo Xu, Hui Wu, Shirong Cai, Yulong He

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

The prognostic value of lactate dehydrogenase levels in the prognosis of colorectal cancer patients has been assessed for years, although the results remain controversial and heterogeneous. Thus, we comprehensively reviewed the evidence from studies that evaluated lactate dehydrogenase levels in colorectal cancer patients to determine their effect.

Methods

The following databases were searched in September 2014 to identify studies that evaluated the prognostic value of lactate dehydrogenase levels in colorectal cancer: PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. We extracted hazard ratios (HRs) and the associated 95 % confidence intervals (CIs) from the identified studies, and performed random-effects model meta-analyses on the overall survival (OS) and progression-free survival (PFS). Thirty-two studies with a cumulative sample size of 8,261 patients were included in our analysis.

Results

Our meta-analyses revealed that high levels of lactate dehydrogenase were associated with poor OS (HR, 1.75; 95 % CI, 1.52–2.02) in colorectal cancer patients. However, this effect was not obvious in the OS of non-metastatic colorectal cancer patients (HR, 1.21; 95 % CI, 0.79–1.86). The prognostic value of lactate dehydrogenase levels on PFS was also not confirmed (HR, 1.36; 95 % CI, 0.98–1.87). Subgroup analyses revealed that the prognostic significance of lactate dehydrogenase was independent of study location, patient age, number of patients, metastasis, chemotherapy with anti-angiogenesis drugs, study type, or risk of bias.

Conclusions

Our results indicate that high lactate dehydrogenase levels are associated with poor OS among colorectal cancer patients, although these levels are not significant predictors of PFS.
Appendix
Available only for authorised users
Literature
1.
2.
Galizia G, Gemei M, Del Vecchio L, Zamboli A, Di Noto R, Mirabelli P, et al. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg. 2012;147(1):18–24.CrossRefPubMed
3.
Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57(3):168–85.CrossRefPubMed
4.
5.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.CrossRefPubMedPubMedCentral
6.
7.
Suh SY, Ahn HY. Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: a preliminary study. Eur J Cancer. 2007;43(6):1051–9.CrossRefPubMed
8.
Higgins JP GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. Cochrane Collaboration 2009.
9.
Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138(5):1714–26.CrossRefPubMed
10.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.CrossRefPubMed
11.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.CrossRefPubMedPubMedCentral
12.
13.
Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820–6.CrossRefPubMed
14.
15.
Agrawal K, Jain S, Pattali S, Singh A, Agrawal K, Cleveland B, et al. Factors affecting overall survival in a minority-based population of young colorectal cancer patients: A single-institution multivariate analysis. Am J Gastroenterol. 2013;108:S628.CrossRef
16.
Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, et al. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. Eur J Cancer. 2014;50(11):1973–81.CrossRefPubMed
17.
Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, et al. Comorbidity, age and overall survival in cetuximabtreated patients with advanced colorectal cancer (ACRC)-results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care. Ann Oncol. 2011;22(1):118–26.CrossRefPubMed
18.
Caputo D, Caricato M, Vincenzi B, La Vaccara V, Masciana G, Coppola R. Serum lactate dehydrogenase alone is not a helpful prognostic factor in resected colorectal cancer patients. Updates Surg. 2014;66(3):211–5. doi:10.​1007/​s13304-014-0260-5. Epub 2014 Aug 8.CrossRefPubMed
19.
Cetin B, Kaplan MA, Berk V, Ozturk SC, Benekli M, Isikdogan A, et al. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents. Asian Pac J Cancer Prev. 2012;13(3):1059–63.CrossRefPubMed
20.
Chibaudel B, Bonnetain F, Tournigand C, Bengrine-Lefevre L, Teixeira L, Artru P, et al. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. In: Oncologist; 2011. p. 1228–38.
21.
Diouf M, Chibaudel B, Filleron T, Tournigand C, Hug de Larauze M, Garcia-Larnicol ML, et al. Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study. Health Qual Life Outcomes. 2014;12(1):69.CrossRefPubMedPubMedCentral
22.
Formica V, Cereda V, Di Bari MG, Grenga I, Tesauro M, Raffaele P, et al. Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). Med Oncol. 2013;30(4):743.CrossRefPubMed
23.
Galizia G, Lieto E, Orditura M, Castellano P, Imperatore V, Pinto M, et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg. 2008;143(4):352–8.CrossRefPubMed
24.
Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Trarbach T, Folprecht G, et al. Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. Br J Cancer. 2012;107(7):1044–50. doi:10.​1038/​bjc.​2012.​369. Epub 2012 Aug 21.CrossRefPubMedPubMedCentral
25.
Giessen C, Fischer Von Weikersthal L, Laubender RP, Stintzing S, Modest DP, Schalhorn A, et al. Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: A preplanned analysis of the FIRE-1 trial. Br J Cancer. 2013;109(6):1428–36.CrossRefPubMedPubMedCentral
26.
Giessen C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, et al. Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer. Tumor Biology. 2014;35(10):10237.CrossRefPubMed
27.
Hannisdal E, Tveit KM, Theodorsen L, Host H. Host markers and prognosis in recurrent rectal carcinomas treated with radiotherapy. Acta Oncol. 1994;33(4):415–21.CrossRefPubMed
28.
He WZ, Guo GF, Yin CX, Jiang C, Wang F, Qiu HJ, et al. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer. Color Dis. 2013;15(8):e443–52.CrossRef
29.
Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group. J Clin Oncol. 2006;24(26):4301–8. Epub 2006 Aug 8.CrossRefPubMed
30.
Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (Vatalanib) antiangiogenic therapy. Clin Cancer Res. 2011;17(14):4892–900.CrossRefPubMedPubMedCentral
31.
Lin EH, Curley SA, Crane CC, Feig B, Skibber J, Delcos M, et al. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: Potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol. 2006;29(3):232–9.CrossRefPubMed
32.
Lin JT, Wang WS, Yen CC, Liu JH, Yang MH, Chao TC, et al. Outcome of colorectal carcinoma in patients under 40 years of age. J Gastroenterol Hepatol. 2005;20(6):900–5.CrossRefPubMed
33.
Machida N, Yoshino T, Boku N, Hironaka S, Onozawa Y, Fukutomi A, et al. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2008;38(10):689–94.CrossRefPubMed
34.
Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, et al. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 2007;121(5):1066–71.CrossRefPubMed
35.
36.
Philipp AB, Nagel D, Stieber P, Lamerz R, Thalhammer I, Herbst A, et al. Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer. BMC Cancer. 2014;14(1):743.CrossRef
37.
Rambach L, Bertaut A, Vincent J, Lorgis V, Ladoire S, Ghiringhelli F. Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. World J Gastroenterol. 2014;20(6):1565–73.CrossRefPubMedPubMedCentral
38.
Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Anton A, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol. 2005;23(15):3545–51.CrossRefPubMed
39.
Scartozzi M, Giampieri R, MacCaroni E, Del Prete M, Faloppi L, Bianconi M, et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer. 2012;106(5):799–804.CrossRefPubMedPubMedCentral
40.
Shah U, Pendurti G, Swami U, Hou Y, Ghalib MH, Chaudhary I, et al. Clinical outcome for patients with metastatic colorectal cancer (mCRC) enrolled in phase I clinical trials: Single institution experience. J Clin Oncol 2013;31(15).
41.
Shitara K, Yuki S, Yamazaki K, Naito Y, Fukushima H, Komatsu Y, et al. Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. J Cancer Res Clin Oncol. 2013;139(4):595–603.CrossRefPubMed
42.
Suenaga M, Matsusaka S, Takagi K, Kuboki Y, Watanabe T, Shinozaki E, et al. Potential markers predicting bevacizumab efficacy for metastatic colorectal cancer patients. J Clin Oncol 2010;28(15).
43.
44.
Uysal M, Bozcuk H, Sezgin Goksu S, Murat Tatli A, Arslan D, Gunduz S, et al. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab. Biomed Pharmacother. 2014;68(4):409–12.CrossRefPubMed
45.
Van Cutsem E, Bajetta E, Valle J, Kohne CH, Hecht JR, Moore M, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29(15):2004–10.CrossRefPubMed
46.
Wiggers T, Arends JW, Volovics A. Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum. 1988;31(1):33–41.CrossRefPubMed
47.
Yin C, Jiang C, Liao F, Rong Y, Cai X, Guo G, et al. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther. 2014;7:1415–22. doi:10.​2147/​OTT.​S64559. eCollection 2014.CrossRefPubMedPubMedCentral
48.
Bar J, Spencer S, Morgan S, Pike L, Cunningham D, Robertson JD, et al. Correlation of lactate dehydrogenase (LDH) isoenzyme profile with outcome in advanced colorectal cancer (CRC) patients (pts) treated with chemotherapy and bevacizumab (BEV) or cediranib (CED). J Clin Oncol 2012;30(15).
49.
Bidard FC, Tournigand C, Andre T, Mabro M, Figer A, Cervantes A, et al. Efficacy of FOLFIRI-3 (irinotecan D1, D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol. 2009;20(6):1042–7.CrossRefPubMed
50.
Chibaudel B, Tournigand C, Artru P, Andre T, Cervantes A, Figer A, et al. FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: An exploratory cohort of the GERCOR OPTIMOX1 study. Ann Oncol. 2009;20(8):1383–6.CrossRefPubMed
51.
Cierpinski A, Stein A, Russel J, Ettrich T, Schmoll HJ, Arnold D. Prognostic impact of carcino embryonic antigen (CEA), carbohydrate antigen (CA 19–9), and lactate dehydrogenase (LDH) decrease in patients with metastatic colorectal cancer (mCRC) receiving a bevacizumab-or cetuximab-chemotherapy combination. Onkologie. 2011;34:250.
52.
Diouf M, Bonnetain F, Chibaudel B, Tournigand C, Teixeira L, Marijon H, et al. Could baseline health-related quality of life (QoL) improve prognostication of overall survival in metastatic colorectal cancer? Results from GERCOR OPTIMOX 1 study. J Clin Oncol 2011;29(15).
53.
Jain S, Agrawal K, Pattali S, Singh A, Agrawal K, Cleveland B, et al. Multivariate analysis of factors affecting overall survival in minority-based population of young colorectal cancer patients: A single-institution experience. J Clin Oncol 2012;30(15).
54.
Maccaroni E, Giampieri R, Scartozzi M, Del Prete M, Faloppi L, Bianconi M, et al. Pretreatment levels of serum lactate dehydrogenase (LDH) and clinical outcome in metastatic colorectal cancer patients receiving first-line chemotherapy and bevacizumab. J Clin Oncol 2012;30(4).
55.
Mekenkamp LJM, Heesterbeek CJ, Koopman M, Teerenstra S, Venderbosch S, Punt CJA, et al. Prognostic and predictive value of mucinous adenocarcinomas in colorectal cancer patients treated with chemotherapy and targeted therapy. Eur J Cancer. 2011;47:S396.CrossRef
56.
Mekenkamp LJM, Koopman M, Teerenstra S, Van Krieken JHJM, Mol L, Nagtegaal ID, et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer. 2010;103(2):159–64.CrossRefPubMedPubMedCentral
57.
Shitara K, Matsuo K, Yokota T, Takahari D, Shibata T, Ura T, et al. Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. Gastrointestinal Cancer Res. 2011;4(5–6):168–72.
58.
Suenaga M, Matsusaka S, Ueno M, Yamamoto N, Shinozaki E, Mizunuma N, et al. Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients. Surg Today. 2011;41(8):1067–74.CrossRefPubMed
59.
Van Kessel CS, Samim M, Koopman M, Van Den Bosch MAAJ, Borel Rinkes IHM, Punt CJA, et al. Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases. Eur J Cancer. 2013;49(11):2486–93.CrossRefPubMed
60.
Silvestris N, Scartozzi M, Graziano G, Santini D, Lorusso V, Maiello E, et al. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin Biol Ther. 2015;15(2):155–62.CrossRefPubMed
Metadata
Title
The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis
Authors
Guanghua Li
Zhao Wang
Jianbo Xu
Hui Wu
Shirong Cai
Yulong He
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2276-3

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Study protocol

Design of a multicentre randomized controlled trial to evaluate the effectiveness of a tailored clinical support intervention to enhance return to work for gastrointestinal cancer patients

Research article

MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice

Research article

Fusion with stem cell makes the hepatocellular carcinoma cells similar to liver tumor-initiating cells

Research article

“Safety and utility of percutaneous liver biopsy in hematopoietic stem cell transplant pediatric recipients: a retrospective study”

Research article

Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells

Research article

Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits